Review of neurologic diseases for the urologist

Urologic Clinics of North America

Volumn 37, Issue 4, 2010, Pages 517-526

  Fowler, Clare J ^a   Dalton, Catherine ^a   Panicker, Jalesh N ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Frontal lobes; Geriatric incontinence; MSA; Multiple sclerosis; Neurology of bladder control; Parkinson's disease

Indexed keywords

ALEMTUZUMAB; CLADRIBINE; DOPAMINE RECEPTOR STIMULATING AGENT; FINGOLIMOD; GLATIRAMER; INTERFERON; LEVODOPA; NATALIZUMAB;

AGING; BLADDER DYSFUNCTION; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ENCEPHALITIS; FRONTAL LOBE; HERPES ZOSTER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMPAIRED BLADDER EMPTYING; LOWER URINARY TRACT SYMPTOM; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC DISEASE; PARKINSON DISEASE; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SHY DRAGER SYNDROME; SKIN CANCER; THYROID DISEASE; URINE INCONTINENCE; UROLOGY; WHITE MATTER;

AGING; FRONTAL LOBE; MULTIPLE SCLEROSIS; MULTIPLE SYSTEM ATROPHY; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE; UROLOGY;

EID: 77957927206     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2010.07.004     Document Type: Review

References (63)

1. Pelvic organ dysfunction in neurological disease 2010, Cambridge University Press, Cambridge. C.J. Fowler, J.N. Panicker, A. Emmanuel (Eds.).
2. Campbell-Walsh urology review manual 2010, Amsterdam: Saunders Elsevier. 3rd edition. A.J. Wein, L.R. Kavoussi, A.C. Novick (Eds.).
3. Andrew J., Nathan P.W. Lesions on the anterior frontal lobes and disturbances of micturition and defaecation. Brain 1964, 87:233-262.
4. Fowler C.J., Griffiths D.J. A decade of functional brain imaging applied to bladder control. Neurourol Urodyn 2010, 29(1):49-55.
5. Holstege G., Bandler R., Saper C.B. The emotional motor system. Prog Brain Res 1996, 107:3-6.
6. Griffiths D., Tadic S.D. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn 2008, 27(6):466-474.
7. Fowler C.J., Griffiths D., de Groat W.C. The neural control of micturition. Nat Rev Neurosci 2008, 9(6):453-466.
8. Craig A.D. How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev Neurosci 2002, 3(8):655-666.
9. Milsom I., Abrams P., Cardozo L., et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001, 87(9):760-766.
10. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20(6):327-336.
11. Inouye S.K., Studenski S., Tinetti M.E., et al. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 2007, 55(5):780-791.
12. Kuo H.K., Lipsitz L.A. Cerebral white matter changes and geriatric syndromes: is there a link?. J Gerontol A Biol Sci Med Sci 2004, 59(8):818-826.
13. Sakakibara R., Hattori T., Uchiyama T., et al. Urinary function in elderly people with and without leukoaraiosis: relation to cognitive and gait function. J Neurol Neurosurg Psychiatry 1999, 67(5):658-660.
14. Poggesi A., Pracucci G., Chabriat H., et al. Urinary complaints in nondisabled elderly people with age-related white matter changes: the Leukoaraiosis And DISability (LADIS) Study. J Am Geriatr Soc 2008, 56(9):1638-1643.
15. Kuchel G.A., Moscufo N., Guttmann C.R., et al. Localization of brain white matter hyperintensities and urinary incontinence in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 2009, 64(8):902-909.
16. Gilman S., Wenning G.K., Low P.A., et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71(9):670-676.
17. Yamamoto T., Sakakibara R., Uchiyama T., et al. Questionnaire-based assessment of pelvic organ dysfunction in multiple system atrophy. Mov Disord 2009, 24(7):972-978.
18. Sakakibara R., Hattori T., Uchiyama T., et al. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001, 71(5):600-606.
19. Benarroch E.E., Schmeichel A.M., Low P.A., et al. Involvement of medullary serotonergic groups in multiple system atrophy. Ann Neurol 2004, 55(3):418-422.
20. Yoshida M. Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 2007, 27(5):484-493.
21. Ito T., Sakakibara R., Yasuda K., et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it?. Mov Disord 2006, 21(6):816-823.
22. Hahn K., Ebersbach G. Sonographic assessment of urinary retention in multiple system atrophy and idiopathic Parkinson's disease. Mov Disord 2005, 20(11):1499-1502.
23. Kirby R.S., Fowler C.J., Gosling J., et al. Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. J Neurol Neurosurg Psychiatry 1986, 49:554-562.
24. Mashidori T., Yamanishi T., Yoshida K., et al. Continuous urinary incontinence presenting as the initial symptoms demonstrating acontractile detrusor and intrinsic sphincter deficiency in multiple system atrophy. Int J Urol 2007, 14(10):972-974.
25. Sakakibara R., Uchiyama T., Yamanishi T., et al. Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm 2008, 115(3):443-460.
26. Palace J., Chandiramani V.A., Fowler C.J. Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve 1997, 20(11):1396-1403.
27. Tison F., Arne P., Sourgen C., et al. The value of external anal sphincter electromyography for the diagnosis of multiple system atrophy. Mov Disord 2000, 15(6):1148-1157.
28. Giladi N., Simon E.S., Korczyn A.D., et al. Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson's disease. Muscle Nerve 2000, 23:731-734.
29. Paviour D.C., Williams D., Fowler C.J., et al. Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy? A retrospective study with pathological diagnosis. Mov Disord 2005, 20(11):1425-1430.
30. Chaudhuri K.R., Martinez-Martin P., Schapira A.H., et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006, 21(7):916-923.
31. Martinez-Martin P., Schapira A.H., Stocchi F., et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007, 22(11):1623-1629.
32. Sakakibara R., Shinotoh H., Uchiyama T., et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 2001, 92(1-2):76-85.
33. de Groat W.C. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 2006, 147(Suppl 2):S25-S40.
34. Seki S., Igawa Y., Kaidoh K., et al. Role of Dopamine D1 and D1 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 2001, 20(1):105-113.
35. Hineno T., Mizobuchi M., Hiratani K., et al. Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs. Brain Res 1992, 580(1-2):92-99.
36. Stocchi F., Carbone A., Inghilleri M., et al. Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 1997, 62:507-511.
37. Wheeler J.S., Siroky M.B., Pavlakis A.J., et al. The changing neurourologic pattern of multiple sclerosis. J Urol 1983, 130:1123-1126.
38. Sakakibara R., Uchiyama T., Yamanishi T., et al. Genitourinary dysfunction in Parkinson's disease. Mov Disord 2010, 25(1):2-12.
39. Braak H., Ghebremedhin E., Rüb U., et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004, 318(1):121-134.
40. Braak H., Rub U., Gai W.P., et al. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003, 110(5):517-536.
41. Staskin D.S., Vardi Y., Siroky M.B., et al. Post-prostatectomy incontinence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol 1988, 140:117-118.
42. Roth B., Studer U.E., Fowler C.J., et al. Benign prostatic obstruction and Parkinson's disease-should transurethral resection of the prostate be avoided?. J Urol 2009, 181(5):2209-2213.
43. Polman C.H., Reingold S.C., Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the " McDonald Criteria" Ann Neurol 2005, 58(6):840-846.
44. Trapp B.D., Peterson J., Ransohoff R.M., et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338(5):278-285.
45. Brex P.A., Jenkins R., Fox N.C., et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000, 54(8):1689-1691.
46. Coles A.J., Cox A., Le Page E., et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006, 253(1):98-108.
47. Confavreux C., Vukusic S., Moreau T., et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000, 343(20):1430-1438.
48. Confavreux C., Aimard G., Devic M., et al. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980, 103(2):281-300.
49. Confavreux C., Vukusic S., Adeleine P., et al. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003, 126(Pt 4):770-782.
50. Kalita J., Shah S., Kapoor R., et al. Bladder dysfunction in acute transverse myelitis: magnetic resonance imaging and neurophysiological and urodynamic correlations. J Neurol Neurosurg Psychiatry 2002, 73(2):154-159.
51. Awad S.A., Gajewski J.B., Sogbein S.K., et al. Relationship between neurological and urological status in patients with multiple sclerosis. J Urol 1984, 132:499-502.
52. Betts C.D., D'Mellow M.T., Fowler C.J., et al. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993, 56:245-250.
53. Fowler C.J., Panicker J.N., Drake M., et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80(5):470-477.
54. Kalsi V., Gonzales G., Popat R., et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007, 62(5):452-457.
55. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996, 39(3):285-294.
56. Paty D.W., Li D.K. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. Neurology 2001, 57(12 Suppl 5):S10-S15.
57. Comi G., Filippi M., Wolinsky J.S., et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001, 49(3):290-297.
58. Miller D.H., Khan O.A., Sheremata W.A., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348(1):15-23.
59. Polman C.H., O'Connor P.W., Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354(9):899-910.
60. Clifford D., DeLuca A., Simpson D.M., et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010, 9(4):438-446.
61. Giovannoni G., Comi G., Cook S., et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010, 362(5):416-426.
62. Kappos L., Radue E.W., O'Connor P., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362(5):387-401.
63. Coles A.J., Compston D.A., Selmaj K.W., et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359(17):1786-1801.